Pan-Asia Catalysts/Events, Quiddity Advisors

David Blennerhassett

Pan-Asia Catalysts/Events

Quiddity Advisors

Event-Driven

<ul>
<li>MA Financial (13.43% of shares out) and Alison Hughes (9.94%) said they will reject Genesis A$1.8675/share offer for <a href="https://www.smartkarma.com/entities/pacific-smiles-group-ltd" target="_blank" data-smartkarma-citation="entities:2891:1" rel="noopener">Pacific Smiles (PSQ AU)</a>; therefore the 90% acceptance condition cannot be met.</li>
<li>Separately, PSQ's board also rejected terms, as Genesis Offer is below NDC's A$2.05/share Offer; plus terms are "opportunistic" as they do not account for PSQ's recent strong financial improvement. </li>
<li>What now? Genesis has the flexibility to bump. Expect that to occur. They won't fold their tent in response to this latest development.</li>
</ul>


MA Financial (13.43% of shares out) and Alison Hughes (9.94%) said they will reject Genesis A$1.8675/share offer for Pacific Smiles (PSQ AU); therefore the 90% acceptance condition cannot be met.
Separately, PSQ's board also rejected terms, as Genesis Offer is below NDC's A$2.05/share Offer; plus terms are "opportunistic" as they do not account for PSQ's recent strong financial improvement. 
What now? Genesis has the flexibility to bump. Expect that to occur. They won't fold their tent in response to this latest development.


Pacific Smiles: Key Shareholders Reject Genesis' Terms

<ul>
<li>On the 18th July, diagnostic imaging provider <a href="https://www.smartkarma.com/entities/capitol-health-ltd" target="_blank" data-smartkarma-citation="entities:14504:1" rel="noopener">Capitol Health (CAJ AU)</a> entered a Scheme with <a href="https://www.smartkarma.com/entities/integral-diagnostics-ltd" target="_blank" data-smartkarma-citation="entities:24306:1" rel="noopener">Integral Diagnostics (IDX AU)</a>. IDX will issue 0.12849 new IDX shares for each Capitol share</li>
<li>Upon completing the transaction, Integral would hold ~63% in the MergeCo. They key risk is the ACCC signing off. A decision is expected on (or around) the 28th November.  </li>
<li>The Scheme Booklet is <a href="https://announcements.asx.com.au/asxpdf/20240924/pdf/0687rhtyjsbvt0.pdf" target="_blank" rel="noopener">now out</a>, with a Scheme Meeting to be held on the 31st October. Expected implementation on the 14th November. The IE says fair &amp; reasonable.</li>
</ul>


On the 18th July, diagnostic imaging provider Capitol Health (CAJ AU) entered a Scheme with Integral Diagnostics (IDX AU). IDX will issue 0.12849 new IDX shares for each Capitol share
Upon completing the transaction, Integral would hold ~63% in the MergeCo. They key risk is the ACCC signing off. A decision is expected on (or around) the 28th November.  
The Scheme Booklet is now out, with a Scheme Meeting to be held on the 31st October. Expected implementation on the 14th November. The IE says fair &amp; reasonable.


Capitol Health (CAJ AU)/Integral Diagnostics (IDX AU):  31st Oct Merger Vote

Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

Asia Pac IPO & Placement Research, China biotech

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Quantitative Analysis

<ul>
<li>We analyzed the changes in short interest of ASX Stocks as of Sep 13th (reported today) which has an aggregated short interest worth USD25.4bn.</li>
<li>We tabulate league table for top short by value and short as multiple of ADT, as well as weekly increases &amp; decreases in short value, short as multiple of ADT.</li>
<li>We highlight short interest changes in Mineral Resources, Westpac, Gpt, Australian Clinical Labs, Aristocrat Leisure, James Hardie Industries Plc.</li>
</ul>


We analyzed the changes in short interest of ASX Stocks as of Sep 13th (reported today) which has an aggregated short interest worth USD25.4bn.
We tabulate league table for top short by value and short as multiple of ADT, as well as weekly increases &amp; decreases in short value, short as multiple of ADT.
We highlight short interest changes in Mineral Resources, Westpac, Gpt, Australian Clinical Labs, Aristocrat Leisure, James Hardie Industries Plc.


ASX Short Interest Weekly (Sep 13th): Mineral Resources, Westpac, Gpt, Australian Clinical Labs

<ul>
<li>After Crescent Capital 's National Dental Care' (NDC) A$2.05/share Offer, by way of Scheme, failed on the 9 August. it was just a question of when Genesis re-loaded its Offer.</li>
<li>Genesis has now announced a <a href="https://announcements.asx.com.au/asxpdf/20240917/pdf/067yp3mz2w0mbt.pdf" target="_blank" rel="noopener">A$1.90/share off-market Offer</a> (<a href="https://announcements.asx.com.au/asxpdf/20240729/pdf/0660k38ywr0ry3.pdf" target="_blank" rel="noopener"> its 29 July A$1.90/share approach was a Scheme</a>), conditional on a 90% minimum acceptance. Pricing falls within the IE' fair value range.</li>
<li>
<a href="https://www.smartkarma.com/entities/pacific-smiles-group-ltd" target="_blank" data-smartkarma-citation="entities:2891:1" rel="noopener">Pacific Smiles (PSQ AU)</a>'s board previously gave unanimous support for NDC's prior A$1.90/share Offer. The question is whether the 90% hurdle is met. I think it will.</li>
</ul>


After Crescent Capital 's National Dental Care' (NDC) A$2.05/share Offer, by way of Scheme, failed on the 9 August. it was just a question of when Genesis re-loaded its Offer.
Genesis has now announced a A$1.90/share off-market Offer ( its 29 July A$1.90/share approach was a Scheme), conditional on a 90% minimum acceptance. Pricing falls within the IE' fair value range.

Pacific Smiles (PSQ AU)'s board previously gave unanimous support for NDC's prior A$1.90/share Offer. The question is whether the 90% hurdle is met. I think it will.


Pacific Smiles (PSQ AU): Genesis' Off-Market A$1.90/Share Offer

<ul>
<li>We analyzed the changes in short interest of ASX Stocks as of Aug 30th (reported today) which has an aggregated short interest worth USD25.3bn.</li>
<li>We tabulate league table for top short by value and short as multiple of ADT, as well as weekly increases &amp; decreases in short value, short as multiple of ADT.</li>
<li>We highlight short interest changes in Fortescue, Woodside Energy, National Australia Bank, Westpac, Aurizon, CSL, Bluescope Steel.</li>
</ul>


We analyzed the changes in short interest of ASX Stocks as of Aug 30th (reported today) which has an aggregated short interest worth USD25.3bn.
We tabulate league table for top short by value and short as multiple of ADT, as well as weekly increases &amp; decreases in short value, short as multiple of ADT.
We highlight short interest changes in Fortescue, Woodside Energy, National Australia Bank, Westpac, Aurizon, CSL, Bluescope Steel.


ASX Short Interest Weekly (Aug 30th): Fortescue, Woodside Energy, National Australia Bank, Westpac

Australia

Australian Clinical Labs Limited provides health care services. The Company offers routine pathology tests, trimester screening, haematology, histopathology, immunology, and microbiology services. Australian Clinical Labs serves customers in Australia.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Australian Clinical Labs (ACL AU)

Pacific Smiles: Key Shareholders Reject Genesis' Terms

Pacific Smiles (PSQ AU)'s board caves and now recommends shareholders accept the Offer. Genesis Bidco now holds 32.93%, which the board reckons is...

David Blennerhassett

Capitol Health (CAJ AU)/Integral Diagnostics (IDX AU): 31st Oct Merger Vote

Trading wide at a ~5.2%/45% gross/annualised spread. I'm still not comfortable with the ACCC risk here. I'd avoid the arb. I'd be looking...

David Blennerhassett

ASX Short Interest Weekly (Sep 13th): Mineral Resources, Westpac, Gpt, Australian Clinical Labs

We analyzed ASX short interest report for the past week and highlight short interest changes in Mineral Resources, Westpac, Gpt, Australian...

Ke Yan, CFA, FRM

ASX Short Interest Weekly (Aug 30th): Fortescue, Woodside Energy, National Australia Bank, Westpac

We analyzed ASX short interest report for the past week and highlight short interest changes in Fortescue, Woodside Energy, National Australia...

Ke Yan, CFA, FRM

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Pacific Smiles: Key Shareholders Reject Genesis' Terms

Pacific Smiles (PSQ AU)'s board caves and now recommends shareholders accept the Offer. Genesis Bidco now holds 32.93%, which the board reckons is...

David Blennerhassett

Capitol Health (CAJ AU)/Integral Diagnostics (IDX AU): 31st Oct Merger Vote

Trading wide at a ~5.2%/45% gross/annualised spread. I'm still not comfortable with the ACCC risk here. I'd avoid the arb. I'd be looking...

David Blennerhassett

ASX Short Interest Weekly (Sep 13th): Mineral Resources, Westpac, Gpt, Australian Clinical Labs

We analyzed ASX short interest report for the past week and highlight short interest changes in Mineral Resources, Westpac, Gpt, Australian...

Ke Yan, CFA, FRM

Pacific Smiles (PSQ AU): Genesis' Off-Market A$1.90/Share Offer

Trading at a 2.1/11.1% gross/annualised spread, assuming mid-late November payment. If not in, get involved here, and on any dips.

David Blennerhassett

ASX Short Interest Weekly (Aug 30th): Fortescue, Woodside Energy, National Australia Bank, Westpac

We analyzed ASX short interest report for the past week and highlight short interest changes in Fortescue, Woodside Energy, National Australia...

Ke Yan, CFA, FRM